Cross-Sector entity

ICD-10

Company
5

ICD-10 is most often covered alongside CDC National Center for Injury Prevention and Control, which appears in 2 of these 2 stories. clinical-trial accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. The tracked stories average 2 original sources each.

2 verified stories tracked

Last mentioned: Aug 7, 2026

Entity pulse

Recent coverage · ICD-10

2 stories
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about ICD-10

ICD-10 is most often covered alongside CDC National Center for Injury Prevention and Control, which appears in 2 of these 2 stories. clinical-trial accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. The tracked stories average 2 original sources each. ICD-10 appears in 2 tracked Cross-Sector stories from August 7, 2026.

Stories tracked
2
Sources per story
2

Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering ICD-10. Shared-story counts are live from our verified record — not editorial picks.

Stories mentioning ICD-10 2

Healthcare regulation Neutral 5

16% CHS ED Visit Spike After New ICD-10 Code: Hospital Burden Exposed

The introduction of a dedicated ICD-10 code for cannabis hyperemesis syndrome triggered a 16% jump in emergency department diagnoses, unmasking a massive hidden burden on U.S. hospitals. With 200,000 prior ED visits and 2.75 million annual sufferers, health systems must now manage increased demand, train clinicians, and integrate the new code into EHRs and population health analytics.

2 sources
Biotech clinical trial Neutral 5

2.75M Americans with CHS: Biotech Opportunity After 16% Diagnosis Jump

With 2.75 million suffering from cannabis hyperemesis syndrome and a 16% jump in ED diagnoses after a new ICD code, an underserved patient population emerges. Biopharma companies can explore targeted therapies for CHS, a condition currently managed only with abstinence and supportive care, presenting a significant unmet medical need.

2 sources

Source: troyrecord.com · MedPage Today